24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
FLULIEVA 10MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | FLULIEVA 10MG |
|---|---|
| Composition | Fludarabine Phosphate for Injection 10mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
FLULIEVA 10MG (Fludarabine Phosphate for Injection 10mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
FLULIEVA 10 MG (Fludarabine Phosphate for Injection 10 mg) is a prescription anticancer medicine used for the treatment of certain blood cancers and hematological disorders, particularly Chronic Lymphocytic Leukemia (CLL) and selected lymphoid malignancies. It contains Fludarabine Phosphate 10 mg, a potent chemotherapy medicine belonging to the class of drugs known as purine analog antimetabolites. The medicine works by interfering with the DNA synthesis process of abnormal cancer cells, helping to slow disease progression and improve treatment outcomes.
Blood cancers occur when abnormal white blood cells multiply uncontrollably and accumulate in the blood, bone marrow, lymph nodes, and other organs. These abnormal cells interfere with the production and function of healthy blood cells, increasing the risk of infections, anemia, and bleeding disorders. FLULIEVA 10 MG targets these abnormal cells by disrupting their ability to grow and divide, ultimately helping to reduce the number of cancerous cells in the body.
Fludarabine is widely recognized in modern hematology and oncology as an effective treatment option for specific leukemias and lymphoid cancers. It is frequently used alone or in combination with other anticancer medicines as part of comprehensive treatment plans developed by hematologists and oncologists.
FLULIEVA 10 MG is commonly prescribed for:
The medicine may be recommended when patients require systemic therapy to control disease progression or when previous treatment options have not produced the desired clinical response.
Manufactured under strict pharmaceutical quality standards, FLULIEVA 10 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals in hospitals, oncology centers, and specialized hematology treatment facilities.
Patients receiving Fludarabine therapy often require regular blood tests, immune system monitoring, kidney function assessments, and ongoing medical evaluations to ensure safe and effective treatment.
Due to its established effectiveness in managing blood cancers, FLULIEVA 10 MG remains an important component of modern hematology and oncology care worldwide.
FLULIEVA 10 MG (Fludarabine Phosphate for Injection 10 mg) is primarily used for the treatment and management of blood cancers and related hematological disorders.
The medicine is widely used in patients diagnosed with chronic lymphocytic leukemia.
Doctors may prescribe Fludarabine for certain forms of B-cell leukemia requiring systemic therapy.
The medicine may be used in selected cases of low-grade or indolent non-Hodgkin lymphoma.
FLULIEVA may help manage blood cancers that have returned after previous treatment.
The medicine is frequently used alongside other anticancer medicines to improve treatment effectiveness.
Fludarabine supports comprehensive management of blood cancers and hematological disorders.
Fludarabine belongs to a class of medicines known as Purine Analog Antimetabolites.
FLULIEVA works by:
This targeted mechanism helps slow the advancement of blood cancers and improve treatment outcomes.
Like all chemotherapy medicines, FLULIEVA 10 MG may cause side effects in some patients. Side effects vary depending on treatment duration, dosage, and individual patient response.
Weakness and tiredness are commonly reported during treatment.
Mild fever may occur as a result of therapy.
Patients may experience mild to moderate nausea.
Some individuals may develop episodes of vomiting.
Reduced appetite may affect nutritional intake.
Digestive disturbances and loose stools may occur.
Fludarabine may weaken the immune system and increase susceptibility to infections.
Respiratory symptoms such as cough may occasionally occur.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of FLULIEVA 10 MG (Fludarabine Phosphate for Injection 10 mg) should always be determined by a qualified hematologist or oncologist.
Treatment schedules vary according to the diagnosed condition.
Dosage is commonly calculated according to body size.
Patients with kidney impairment may require dosage adjustments.
Treatment decisions often depend on laboratory test results.
Doctors may modify therapy based on effectiveness and side effect management.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of chronic lymphocytic leukemia and certain lymphoid malignancies.
Fludarabine Phosphate is a purine analog chemotherapy medicine that interferes with DNA synthesis in cancer cells.
Yes, it is a chemotherapy medicine used in hematology and oncology treatment programs.
Yes, it is often included in combination chemotherapy regimens.
Yes, the medicine may reduce immune function and increase susceptibility to infections.
Yes, treatment may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Yes, doctors typically recommend blood tests, kidney function assessments, and routine medical evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in hematology and oncology treatment.